LYELL IMMUNOPHARMA INC (LYEL) Stock Balance Sheet
NASDAQ:LYEL - Nasdaq - US55083R1041 - Common Stock - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 120.33M | 105.60M | 145.65M | 123.60M | 293.80M | |||
| Marketable Securities | 180.85M | 264.93M | 400.58M | 516.60M | 321.00M | |||
| Other Current Assets | 8.00M | 9.07M | 8.46M | 11.10M | 11.50M | |||
| Total Current Assets | 309.18M | 379.59M | 554.69M | 651.30M | 626.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 67.77M | 72.94M | 142.32M | 166.30M | 166.60M | |||
| Investments And Advances | 47.95M | 32.01M | 48.51M | 115.00M | 330.50M | |||
| Other Non-Current Assets | 4.91M | 6.31M | 4.52M | 5.00M | 3.90M | |||
| Total Non-Current Assets | 120.62M | 111.27M | 195.34M | 286.30M | 501.10M | |||
| TOTAL ASSETS | 429.80M | 490.86M | 750.03M | 937.60M | 1.13B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 31.17M | 37.34M | 26.63M | 26.40M | 27.60M | |||
| Accounts Payable | 3.73M | 5.37M | 4.82M | 3.90M | 3.20M | |||
| Other Current Liabilities | 6.39M | 11.08M | 3.07M | 6.70M | 15.90M | |||
| Total Current Liabilities | 41.28M | 53.79M | 34.52M | 37.00M | 46.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 51.99M | 54.25M | 60.56M | 67.30M | 150.90M | |||
| Total Non-Current Liabilities | 51.99M | 54.25M | 60.56M | 67.30M | 150.90M | |||
| TOTAL LIABILITIES | 93.28M | 108.03M | 95.08M | 104.30M | 197.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.40B | -1.35B | -1.00B | -767.50M | -584.40M | |||
| Additional Paid In Capital | 1.73B | 1.73B | 1.66B | 1.61B | 1.52B | |||
| Common Shares | 30.00K | 29.00K | 25.00K | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 158.00K | 291.00K | -94.00K | -7.60M | -1.60M | |||
| Shares Outstanding | 295.28M | 294.88M | 253.96M | 249.60M | 242.70M | |||
| Tangible Book Value per Share | 1.14 | 1.30 | 2.58 | 3.34 | 3.83 | |||
| Total Shareholders' Equity | 336.52M | 382.82M | 654.95M | 833.30M | 929.80M | |||
| TOTAL LIABILITIES AND EQUITY | 429.80M | 490.86M | 750.03M | 937.60M | 1.13B | |||
| Statistics | ||||||||
| Current Ratio | 7.49 | 7.06 | 16.07 | 17.60 | 13.41 | |||
| Return On Assets (ROA) | -77.83% | -69.88% | -31.28% | -19.53% | -22.19% | |||
| Return On Equity (ROE) | -99.41% | -89.60% | -35.82% | -21.98% | -26.91% | |||
All data in USD , ROIC based on taxRate of 0.21